会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 15. 发明授权
    • Pharmaceutical composition and preparation for oral administration
    • 药物组合物和口服制剂
    • US08815262B2
    • 2014-08-26
    • US13575547
    • 2011-01-27
    • Shigetomo Tsujihata
    • Shigetomo Tsujihata
    • A61K31/337A61L31/00
    • A61L31/00A61K9/0095A61K9/10A61K9/5138A61K9/5192A61K31/337A61K38/13
    • A pharmaceutical composition including drug-containing nanoparticles having an average particle diameter of from 10 nm to 150 nm, the pharmaceutical composition being obtained by mixing water with a poorly water soluble drug-containing, water miscible solution that contains a poorly water soluble drug having a water solubility of 50 μg/mL or less, a water soluble copolymer having a repeating unit represented by the following Formula (1), and a water miscible miscible solvent, wherein in Formula (1), n:m is within a range of from 0.25:0.75 to 0.95:0.05, R represents an alkyl group which may have a substituent, R1 and R2 each independently represent a hydrogen atom or a methyl group, and Me represents a methyl group; and a preparation for oral administration, which includes the pharmaceutical composition.
    • 一种药物组合物,其包含平均粒径为10nm〜150nm的含药纳米粒子,所述药物组合物通过将水与水溶性差的药物的水溶性溶液混合而获得,所述溶液含有水溶性差的药物,所述药物组合物具有 水溶性为50μg/ mL以下,具有由下式(1)表示的重复单元的水溶性共聚物和水混溶性混溶性溶剂,式(1)中,n:m为 0.25:0.75〜0.95:0.05,R表示可以具有取代基的烷基,R 1和R 2各自独立地表示氢原子或甲基,Me表示甲基。 和口服给药制剂,其包括药物组合物。